Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Devon A. Lukow"'
Autor:
Jason M. Sheltzer, Devon A. Lukow
Publikováno v:
Trends in cancer. 8(1)
High levels of aneuploidy and chromosomal instability (CIN) are correlated with poor patient outcomes, though the mechanism(s) underlying this relationship have not been established. Recent evidence has demonstrated that chromosome copy number change
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8ed3e08e23c15694d191d1f6fd5cf4
https://pubmed.ncbi.nlm.nih.gov/34593353
https://pubmed.ncbi.nlm.nih.gov/34593353
Autor:
Pavit Suri, Jason M. Sheltzer, Zuzana Storchova, Zihua Wang, Narendra Kumar Chunduri, Erin L. Sausville, Justin Leu, Jude Kendall, Devon A. Lukow
Aneuploidy is a ubiquitous feature of human tumors, but the acquisition of aneuploidy is typically detrimental to cellular fitness. To investigate how aneuploidy could contribute to tumor growth, we triggered periods of chromosomal instability (CIN)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85cc3407d742c7e632c1e45cba8c2dce
https://doi.org/10.1101/2020.09.25.314229
https://doi.org/10.1101/2020.09.25.314229
Autor:
Zihua Wang, Pavit Suri, Narendra Kumar Chunduri, Zuzana Storchova, Devon A. Lukow, Justin Leu, Erin L. Sausville, Jude Kendall, Ankith A. Kumar, Joan C. Smith, Angela Wieland, Jason M. Sheltzer, Vishruth Girish
Publikováno v:
Dev Cell
Aneuploidy is a ubiquitous feature of human tumors, but the acquisition of aneuploidy typically antagonizes cellular fitness. To investigate how aneuploidy could contribute to tumor growth, we triggered periods of chromosomal instability (CIN) in hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b14232cba47c9d9efc945a21502095e0
https://doi.org/10.1016/j.devcel.2021.07.009
https://doi.org/10.1016/j.devcel.2021.07.009
Autor:
Zachary C. Galluzzo, Ann Lin, Christopher J. Giuliano, Jason M. Sheltzer, Connor Abramowicz, Luwei Liu, Alexander R. Chait, Erin L. Sausville, Kristen M. John, Ann C. Palladino, Devon A. Lukow, Clara Tucker, Monet Lou Yuan
Publikováno v:
Sci Transl Med
Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology never advance to receive U.S. Food and Drug Administration approval. While lack of efficacy and dose-limiting toxicities are the most common causes of trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::601dae8a25111fc2527d4f970c618ff8
https://doi.org/10.1126/scitranslmed.aaw8412
https://doi.org/10.1126/scitranslmed.aaw8412